|
PRESCRIRE'S RATINGS
Our ratings indicate whether a product represents a therapeutic advance in the relevant clinical situation. We consider not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
|
 |
BRAVO
A clear and major therapeutic advance in a particularly poorly served field.
|
 |
A REAL ADVANCE
An important therapeutic advance but with certain limitations.
|
 |
OFFERS AN ADVANTAGE
Offers some value but does not fundamentally change current therapeutic practice.
|
 |
POSSIBLY HELPFUL
Offers minimal additional value, and should not change prescribing habits except in rare circumstances.
|
 |
NOTHING NEW
Not shown to represent a therapeutic advance.
|
 |
NOT ACCEPTABLE
Offers no evident benefit but has potential or real disadvantages.
|
 |
JUDGEMENT RESERVED
The editors postpone their rating until better data and a more thorough evaluation of the product are available.
|
The Prescrire Drug Awards for 2025
Download the full article:

"The Prescrire Awards for 2025" Prescrire Int 2026; 35 (281): 134-138. FREE.
Back to "The Prescrire Awards for 2025"

|
Enjoy full access to Prescrire International, and support independent medical information
|